EGFR and hepatocellular carcinoma: In a separate experiment, HCC-1143 cells were treated with EGFR monoclonal antibody cetuximab for 48 hours to inhibit EGFR-mediated intracellular signaling, followed by five minutes of treatment with IFN-γ alone or TNF-α and IFN-γ.